Product Information
TOPIRAMATE 25 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.0268 per EA under NDC 69097012212. Its NADAC has been published 610 times since Jan 28, 2015.
FDA first approved this application on Mar 27, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Cipla USA Inc.NDC
69097012212
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA076343FDA Approved
3/27/2009
TE Code
AB
On Market Since
6/12/2014
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE 25 MG TABLET has been published 610 times since Jan 28, 2015, and over the history we have for it it has declined 23.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0268 per EA |
|---|---|
| All-time high | $0.0391 (Sep 14, 2016) |
| All-time low | $0.0221 (Jul 17, 2024) |
| 52-week high | $0.0270 |
| 52-week low | $0.0254 |
| Median price | $0.0331 |
| Average price | $0.0318 |
| Largest weekly change | -29.1% (Jul 17, 2024) |
| Weeks tracked | 610 |
| Tracking since | Jan 28, 2015 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE 25 MG TABLET, manufactured by Cipla USA Inc., is $0.0268 per EA (NDC 69097012212), effective Sep 30, 2026.
How has the price of TOPIRAMATE 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE 25 MG TABLET has declined 23.1%. It has been tracked across 610 weekly CMS publications since Jan 28, 2015.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE 25 MG TABLET?
Since Jan 28, 2015, the NADAC for TOPIRAMATE 25 MG TABLET has ranged from a low of $0.0221 (Jul 17, 2024) to a high of $0.0391 (Sep 14, 2016), with a median of $0.0331 per EA.
Are there cheaper alternatives to TOPIRAMATE 25 MG TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE 25 MG TABLET, is $0.0256 per EA — about 5% below TOPIRAMATE 25 MG TABLET.
Who manufactures TOPIRAMATE 25 MG TABLET?
TOPIRAMATE 25 MG TABLET (NDC 69097012212) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.